COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal

Journal of Heart and Lung Transplantation

Volumn 39, Issue 5, 2020, Pages 405-407

  Siddiqi, Hasan K ^a   Mehra, Mandeep R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOPINAVIR PLUS RITONAVIR; REMDESIVIR; TOCILIZUMAB;

CHINA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORONAVIRUS DISEASE 2019; COUGHING; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG USE; EDITORIAL; FEVER; GERIATRIC PATIENT; HEART TRANSPLANTATION; HUMAN; HYPOXIA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALAISE; PERSONAL HYGIENE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SOCIAL DISTANCE; SYSTEMIC HYPERINFLAMMATION; THORAX RADIOGRAPHY; VIRUS VIRULENCE; BETACORONAVIRUS; CORONAVIRINAE; CORONAVIRUS INFECTION; EPIDEMIC; PANDEMIC; QUESTIONNAIRE; VIRUS PNEUMONIA;

BETACORONAVIRUS; CHINA; CORONAVIRUS; CORONAVIRUS INFECTIONS; DISEASE OUTBREAKS; HEART TRANSPLANTATION; PANDEMICS; PNEUMONIA, VIRAL; SURVEYS AND QUESTIONNAIRES;

EID: 85083702329     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2020.03.012     Document Type: Editorial

References (11)

1. Novel coronavirus pneumonia emergency response epidemiology team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 41 (2020), 145–151.
2. Wang, M, Cao, R, Zhang, L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30 (2020), 269–271.
3. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [e-pub ahead of print]. N Engl J Med doi: 10.1056/NEJMoa2001282, Accessed March 15, 2020.
4. Russell, CD, Millar, JE, Baillie, JK, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395 (2020), 473–475.
5. Li, F, Cai, J, Dong, N, First cases of COVID-19 in heart transplantation From China. J Heart Lung Transplant 39 (2020), 418–419.
6. Aslam, S, Mehra, MR, COVID-19: yet another coronavirus challenge in transplantation. J Heart Lung Transplant 39 (2020), 408–409.
7. Ren, Z-L, Hu, R, Wang, Z-W, et al. Epidemiological and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: a descriptive survey report. J Heart Lung Transplant 39 (2020), 412–417 doi: 10.1016/j.healun.2020.03.008.
8. Wan, Y, Shang, J, Graham, R, Baric, RS, Li, F, Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol, 94, 2020 e00127-20.
9. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China [e-pub ahead of print]. Clin Infect Dis doi: 10.1093/cid/ciaa248, Accessed March 15, 2020.
10. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China [e-pub ahead of print]. JAMA Intern Med doi: 10.1001/jamainternmed.2020.0994, Accessed March 15, 2020.
11. Mehta P, McAuley DF, Brown M,et al. COVID-19: consider cytokine storm syndromes and immunosuppression [e-pub ahead of print]. Lancet doi: 10.1016/S0140-6736(20)30628-0, Accessed March 15, 2020.